Search

everythinglearnresearchcommunity

for

Search:↓

CD28 is a promising target for treating alopecia areata with belatacept.

CD28 is a promising target for treating alopecia areata with belatacept.

Trastuzumab deruxtecan is effective for HER2-positive breast cancer but requires careful management of side effects.

Belatacept may be a promising treatment for alopecia areata.

γδTregs may help treat autoimmune diseases like alopecia areata by promoting hair regrowth and reducing immune attacks.

γδ T cells can prevent and treat alopecia areata, offering a new therapy option.

TAK-279 effectively reduces psoriasis symptoms and is safe.

Increased TEMRA cells can predict treatment outcomes in rapidly progressive alopecia areata.

Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

Monoclonal antibodies LT-1, LT-2, and LT-7 help diagnose certain blood cancers.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.

Enhancing regulatory T cells may help treat autoimmune diseases like alopecia areata.

Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.

Activating Tgr5 may help treat hair loss and bone loss.

A new carrier improves skin delivery of tofacitinib for treating inflammatory skin diseases.

Targeting vitamin D and androgen receptors may effectively treat triple-negative breast cancer, especially with chemotherapy.

Enhancing immune response can improve cancer treatment effectiveness.

Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.

Promising cancer treatments were found, but the manufacturer closed.

Tofacitinib improved ulcerative colitis, skin ulcers, and hair loss in a patient who didn't respond well to other treatments.

Newly designed proteins can effectively degrade specific proteins in cells, offering a promising alternative for targeted protein degradation.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

TRIV-509 quickly improves skin barrier and cell health in atopic dermatitis.

Thyroid receptor β can help develop new drugs to treat hair loss.

Chronic refractory alopecia areata has more skin-resident memory T cells, and JAK inhibitors may help reduce them.